Explore Business Standard
The Karnataka government has directed all enforcement officers to maintain strict vigil over certain cough syrups following reports of child deaths linked to their consumption in Madhya Pradesh and Rajasthan. In a circular dated October 5, the Food Safety and Drugs Administration (FSDA) said that in view of recent incidents where deaths have been reported in Madhya Pradesh following the consumption of Coldrif Syrup (Batch No. SR-13), manufactured by a Tamil Nadu-based pharma unit, the Tamil Nadu Drugs Control Department has prohibited the purchase, sale and consumption of the said batch in that state. Further, a few deaths of children have been reported in Rajasthan due to the consumption of Dextromethorphan Hydrobromide Syrup IP, manufactured by Kaysons Pharma, Jaipur, it stated. "All enforcement officers in the state of Karnataka are hereby instructed to keep a strict vigil on the above drugs/batch number and similar combinations from manufacturers. Any stockist, distributor, ...
Achieving a 'Bimari Mukt Bharat' or disease-free India is important for realising the goal of 'Viksit Bharat' by 2047, feels social activist and entrepreneur Dr Swapna Verma, who is spearheading a project to deliver tech-enabled diagnostic services at the doorsteps of rural and tribal communities. Verma was among the 10 'pathbreakers' whom Prime Minister Narendra Modi met earlier this month during the Viksit Bharat Young Leaders' Dialogue-2025. Hailing from Satna district in Madhya Pradesh, Verma is the founder of the Madhurima Sewa Sanskar Sansthan. During the young leaders' dialogue at the National Youth Festival, Verma outlined her organisation's flagship project -- 'Heal Rural India' -- before the prime minister, highlighting the scalability of the initiative. Recounting her first meeting with Modi, Verma, who is also part of the Madhya Pradesh BJP unit, said the prime minister asked her how the 'Heal Rural India' project can help make 'Bharat' become 'Bimari Mukt'. "I explain
Genetic defects underlie about a fourth of Chinese children affected by cerebral palsy, and not a lack of oxygen at birth as previously thought, new research has found. Cerebral palsy is a disorder affecting one's ability to move. It is the most common motor disability in children, with symptoms emerging in infancy and early childhood. The disability is sometimes also associated with autism and intellectual deficiencies. Birth asphyxia, or receiving insufficient oxygen at the time of being born, can cause physical harm, especially to the brain, and is considered one of the main causes of cerebral palsy. The world's largest study of cerebral palsy genetics, involving more than 1,500 affected Chinese children, found that mutations were significantly higher in a fourth of these children receiving insufficient oxygen at birth. Researchers said this indicated that birth asphyxia could be secondary to the underlying genetic defects. The results, published in the journal Nature Medicine
India has emerged as a premier destination for conducting global clinical trials, an Indian bureaucrat who is also a Harvard scholar has said, asserting that the pharma industry must recognise the country's intrinsic value as a primary location rather than relegating it to a secondary backup role. Speaking at a recent Bio-Pharma summit in Boston, Dr Mrinalini Darswal, an Indian diplomat who is currently a PhD scholar at Harvard University, said that India "boasts a robust infrastructure, a cadre of seasoned investigators, and cost-effectiveness, collectively rendering it an appealing choice for such endeavours. The present aspirational India under the strong and transformative leadership of our Prime Minister Narendra Modi has emerged as a premier destination for conducting global clinical trials, having streamlined its regulatory framework and elevated its compliance standards to align with international good clinical practices, Darswal said. This starkly contrasts larger economies